Apatinib Prolonged Survival in Advanced Gastric Cancer

Article

The VEGFR-2 tyrosine kinase inhibitor apatinib significantly prolonged overall survival in patients with advanced gastric cancer compared with placebo, according to the results of a phase III study.

The vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor apatinib significantly prolonged overall survival in patients with advanced gastric cancer compared with placebo, according to the results (abstract 4003) of a phase III study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30–June 3 in Chicago.

“Apatinib is the first small molecule–targeting VEGFR to show a survival benefit in advanced gastric cancer,” said Shukui Qin, MD, of PLA Cancer Center of Nanjing Bayi Hospital in Nanjing, China. “Apatinib monotherapy is a new treatment option for advanced gastric cancer patients who failed to second line of chemotherapy.”

According to Qin, more than 80% of patients who are diagnosed with advanced gastric cancer in China require chemotherapeutic treatment. Additionally, there is a strong unmet need for patients with advanced gastric cancer who fail second-line chemotherapy.

This phase III trial included patients with advanced gastric cancer who had failed prior second-line chemotherapy. The patients were randomly assigned 2:1 to 850-mg apatinib or placebo. The primary endpoint of the study was overall survival.

Results of the study revealed an almost 2-month overall survival advantage for patients assigned apatinib. The median overall survival was 6.5 months for apatinib compared with 4.7 months for placebo (P = .0027).

Progression-free survival endpoints also showed significant differences in favor of apatinib in both the full analysis set (3.6 vs 1.8 months; P < .001) and the per-protocol set (2.8 vs 1.9 months; P < .001) of patients.

The researchers also found that apatinib increased the overall response rate (2.84% vs 0%) and the disease control rate (42.05% vs 8.79%; P < .001) compared with placebo.

Patients assigned apatinib experienced significantly more adverse events compared to patients on placebo (P = .0038). However, apatinib was not found to increase severe adverse events.

Patients assigned apatinib had significantly more leukocytopenia (40.34% vs 8.79%; P < .0001), neutropenia (37.5% vs 9.89%; P < .001), and thrombocytopenia (25% vs 6.59%; P = .0002). Apatinib was also associated with significant increases in proteinuria, hypertension, and hand-foot syndrome.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content